JPWO2021030533A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021030533A5 JPWO2021030533A5 JP2022509126A JP2022509126A JPWO2021030533A5 JP WO2021030533 A5 JPWO2021030533 A5 JP WO2021030533A5 JP 2022509126 A JP2022509126 A JP 2022509126A JP 2022509126 A JP2022509126 A JP 2022509126A JP WO2021030533 A5 JPWO2021030533 A5 JP WO2021030533A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- composition
- salt
- denatured
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (15)
(a)リボ核酸(RNA)を含む混合物を脱塩して、20mM未満の塩濃度を有する低塩分RNA組成物を産生することと、
(b)前記低塩分RNA組成物を60℃より高い温度に加熱して、変性RNAを産生することと、
(c)前記変性RNAを含む組成物を高塩分緩衝液とインライン混合して、変性RNA及び少なくとも50mMの濃度の塩を含む組成物を産生することと、
(d)(c)で産生された前記組成物の前記変性RNAを40℃未満の温度でオリゴdT樹脂に結合させることと、
(e)前記オリゴdT樹脂からRNAを溶出させることと、
を含む、方法。 below,
(a) desalting a mixture comprising ribonucleic acid (RNA) to produce a low-salt RNA composition having a salt concentration of less than 20 mM;
(b) heating the low-salt RNA composition to a temperature greater than 60° C. to produce denatured RNA;
(c) in-line mixing a composition comprising said denatured RNA with a high salt buffer to produce a composition comprising denatured RNA and salt at a concentration of at least 50 mM;
(d) binding the denatured RNA of the composition produced in (c) to an oligo-dT resin at a temperature below 40°C;
(e) eluting the RNA from the oligo-dT resin;
A method, including
(a)リボ核酸(RNA)を含む混合物を脱塩して、2mS/cm未満の導電率を有する低塩分RNA組成物を産生することと、
(b)前記低塩分RNA組成物を60℃より高い温度に加熱して、変性RNAを産生することと、
(c)前記変性RNAを含む組成物を高塩分緩衝液とインライン混合して、変性RNA及び少なくとも5mS/cmの導電率を含む組成物を産生することと、
(d)(c)で産生された前記組成物の前記変性RNAを40℃未満の温度でオリゴdT樹脂に結合させることと、
(e)前記オリゴdT樹脂からRNAを溶出させることと、
を含む、方法。 below,
(a) desalting a mixture comprising ribonucleic acid (RNA) to produce a low-salt RNA composition having a conductivity of less than 2 mS/cm;
(b) heating the low-salt RNA composition to a temperature greater than 60° C. to produce denatured RNA;
(c) in-line mixing a composition comprising said denatured RNA with a high salt buffer to produce a composition comprising denatured RNA and a conductivity of at least 5 mS/cm;
(d) binding the denatured RNA of the composition produced in (c) to an oligo-dT resin at a temperature below 40°C;
(e) eluting the RNA from the oligo-dT resin;
A method, including
(ii)前記高塩分緩衝液は、100mM~1000mMの塩濃度及び/または5mS/cm~85mS/cmの導電率を有する、並びに/あるいは、
(iii)前記低塩分RNA組成物は、1~20mMの塩濃度及び/または0.1~2mS/cmの導電率を有する、並びに/あるいは、
(iv)前記低塩分RNA組成物は、変性剤分子の存在下で加熱され、
任意選択で、前記変性剤分子は、ジメチルスルホキシド、グアニジン、または尿素である、
請求項1~3のいずれか一項に記載の方法。 (i) said salt of (a) and/or (c) comprises NaCl, and/or
(ii) the high salt buffer has a salt concentration of 100 mM to 1000 mM and/or a conductivity of 5 mS/cm to 85 mS/cm, and/or
(iii) the low-salt RNA composition has a salt concentration of 1-20 mM and/or a conductivity of 0.1-2 mS/cm, and/or
(iv) the low-salt RNA composition is heated in the presence of a denaturant molecule;
Optionally, said denaturant molecule is dimethylsulfoxide, guanidine, or urea.
The method according to any one of claims 1-3.
任意選択で、前記HIC樹脂は、2000オングストロームの細孔を有する(ポリ)スチレン-ジビニルベンゼン(PS-DVB)R150ビーズ樹脂である、請求項1~4のいずれか一項に記載の方法。 The desalting comprises binding the RNA to a hydrophobic interaction chromatography (HIC) resin and eluting the RNA from the HIC resin to produce the low salt RNA composition. ,
Optionally, the HIC resin is a (poly)styrene-divinylbenzene (PS-DVB) R150 bead resin with 2000 angstrom pores .
(i)1分未満、少なくとも10秒間、または、10~60、10~30、20~40、もしくは30~60秒間で、並びに/あるいは、
(ii)60℃~90℃の温度で
行われる、
請求項1~5のいずれか一項に記載の方法。 The heating of (b) is
(i) less than 1 minute, at least 10 seconds, or 10-60, 10-30, 20-40, or 30-60 seconds , and/or
(ii) at a temperature between 60°C and 90°C
be done,
The method according to any one of claims 1-5 .
(ii)前記変性RNAを含む組成物をブレークタンクに保管することを、
(b)と(c)との間にさらに含み、
任意選択で、前記変性RNAを含む組成物は、2~8℃で1~5日間、前記ブレークタンクに保管される、
請求項1~6のいずれか一項に記載の方法。 (i) in-line cooling the composition comprising said denatured RNA to a temperature below 60°C or below 40°C , and/or
(ii) storing the composition comprising the denatured RNA in a break tank;
further comprising between (b) and (c);
optionally, the composition comprising said denatured RNA is stored in said break tank at 2-8° C. for 1-5 days ;
A method according to any one of claims 1-6 .
(c)の前記インライン混合は、前記混合物を前記オリゴdT樹脂上に結合させることと並行して行われる、
請求項1~7のいずれか一項に記載の方法。 said in-line mixing of (c) is performed in less than 1 minute; and/or
the in-line mixing of (c) is performed in parallel with binding the mixture onto the oligo-dT resin ;
A method according to any one of claims 1-7 .
(ii)(c)の前記組成物における全RNAのうちの少なくとも90%が、変性RNAを含む、
請求項1~8のいずれか一項に記載の方法。 (i) the composition comprising the denatured RNA produced in (c) has a salt concentration of 50-500 mM and/or a conductivity of 5-85 mS/cm, and/or
(ii) at least 90% of the total RNA in the composition of (c) comprises denatured RNA;
The method according to any one of claims 1-8 .
(ii)前記オリゴdT樹脂は、ポリdTで誘導体化された、2000オングストロームの細孔を有する(ポリ)スチレン-ジビニルベンゼン(PS-DVB)ビーズ樹脂である、並びに/あるいは、
(iii)前記オリゴdT樹脂から溶出された前記RNAは、ポリA鎖含有mRNAを少なくとも90%もしくは少なくとも95%含む、
請求項1~9のいずれか一項に記載の方法。 (i) said bonding of (d) is performed at a temperature of 4° C. to 25° C. and/or in less than 20 minutes , and/or
(ii) the oligo-dT resin is a poly-dT-derivatized (poly)styrene-divinylbenzene (PS-DVB) bead resin with 2000 Angstrom pores, and/or
(iii) the RNA eluted from the oligo-dT resin comprises at least 90% or at least 95% poly A chain-containing mRNA;
A method according to any one of claims 1-9 .
(b)中の前記RNAの変性が、紫外線検出を用いてモニターされる、
請求項1~10のいずれか一項に記載の方法。 the secondary structure of said RNA is monitored before and after (b) using ultraviolet detection, and/or
denaturation of the RNA in (b) is monitored using ultraviolet detection;
A method according to any one of claims 1-10 .
高塩分緩衝液を、変性リボ核酸(RNA)を含む低塩分変性RNA組成物とインラインで混合して、変性RNAを含む高塩分組成物を産生することと、
前記変性RNAをオリゴdT樹脂に結合させることと、
を含む方法。 below,
mixing a high salt buffer in-line with a low salt denatured RNA composition comprising denatured ribonucleic acid (RNA) to produce a high salt composition comprising denatured RNA;
binding the denatured RNA to an oligo-dT resin;
method including.
(ii)前記結合は20分未満で行われる、
請求項12に記載の方法。 (i) the in-line mixing is performed for less than 1 minute prior to binding the denatured RNA to the oligo-dT resin, and/or
(ii) said binding occurs in less than 20 minutes;
13. The method of claim 12 .
任意選択で、前記オリゴdT樹脂から溶出された前記RNAは、ポリA鎖含有mRNAを少なくとも90%または少なくとも95%含む、
請求項12または13に記載の方法。 further comprising eluting the RNA from the oligo-dT resin in a low salt buffer;
optionally, said RNA eluted from said oligo-dT resin comprises at least 90% or at least 95% poly A strand containing mRNA.
14. A method according to claim 12 or 13 .
高塩分緩衝液とのインライン混合の前に、RNAを含み、2mS/cm未満の導電率を有する組成物を、60℃より高い温度に加熱して、変性RNA組成物を産生すること、並びに/あるいは、
(ii)高塩分緩衝液とのインライン混合の前に、RNAを含む混合物を脱塩して、20mM未満の塩濃度を有するRNA組成物を産生することと、及び、
前記20mM未満の塩濃度を有するRNA組成物を、60℃より高い温度に加熱して、前記変性RNA組成物を産生することと、
をさらに含む、請求項12~14のいずれか一項に記載の方法。 (i) heating a composition comprising RNA and a salt concentration of less than 20 mM to a temperature above 60° C. to produce a denatured RNA composition prior to in-line mixing with the high salt buffer ; or
and/ or,
(ii) desalting the RNA-containing mixture prior to in-line mixing with the high salt buffer to produce an RNA composition having a salt concentration of less than 20 mM; and
heating the RNA composition having a salt concentration of less than 20 mM to a temperature greater than 60° C. to produce the denatured RNA composition;
15. The method of any one of claims 12-14 , further comprising
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962886840P | 2019-08-14 | 2019-08-14 | |
US62/886,840 | 2019-08-14 | ||
PCT/US2020/046069 WO2021030533A1 (en) | 2019-08-14 | 2020-08-13 | Processes for purifying downstream products of in vitro transcription |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022544416A JP2022544416A (en) | 2022-10-18 |
JPWO2021030533A5 true JPWO2021030533A5 (en) | 2023-08-21 |
Family
ID=74571243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022509126A Pending JP2022544416A (en) | 2019-08-14 | 2020-08-13 | Processes to Purify Downstream Products of In Vitro Transcription |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220348900A1 (en) |
EP (1) | EP4013865A4 (en) |
JP (1) | JP2022544416A (en) |
CN (1) | CN114269918A (en) |
AU (1) | AU2020329226A1 (en) |
BR (1) | BR112022002548A2 (en) |
CA (1) | CA3149498A1 (en) |
WO (1) | WO2021030533A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
HUE059127T2 (en) | 2015-10-22 | 2022-10-28 | Modernatx Inc | Respiratory virus vaccines |
AU2016366978B2 (en) | 2015-12-10 | 2022-07-28 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
CN109937253B (en) | 2016-09-14 | 2023-06-30 | 摩登纳特斯有限公司 | High-purity RNA composition and preparation method thereof |
WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
MA46766A (en) | 2016-11-11 | 2019-09-18 | Modernatx Inc | INFLUENZA VACCINE |
EP3555289A1 (en) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Rna affinity purification |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
MA48047A (en) | 2017-04-05 | 2020-02-12 | Modernatx Inc | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | Methods for hplc analysis |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
CN111212905A (en) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | RNA polymerase variants |
AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
JP2022521094A (en) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | RNA polymerase variant for co-transcription capping |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022266389A1 (en) * | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Alternative rna purification strategies |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024026005A1 (en) * | 2022-07-28 | 2024-02-01 | Modernatx, Inc. | Methods of rna purification |
CN117603958A (en) * | 2023-11-23 | 2024-02-27 | 江苏耀海生物制药有限公司 | Method for purifying in vitro transcribed mRNA and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU655766A (en) * | 1967-06-06 | 1968-12-12 | William Wake David | Bulk handling bin |
EP0649908A1 (en) * | 1988-07-08 | 1995-04-26 | Cetus Oncology Corporation | Uses of gap gene sequences |
US5763573A (en) * | 1988-08-10 | 1998-06-09 | Chiron Corporation | GTPase activating protein fragments |
ATE181332T1 (en) * | 1989-08-21 | 1999-07-15 | Chiron Corp | PEPTIDES DERIVED FROM GTPASE ACTIVATE PROTEIN (GAP) AND THEIR DIAGNOSTIC AND THERAPEUTIC USE |
AU673810B2 (en) * | 1991-10-16 | 1996-11-28 | Chiron Corporation | Secreted Mac-2-binding glycoprotein |
EP2971161B1 (en) * | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
-
2020
- 2020-08-13 CN CN202080059135.9A patent/CN114269918A/en active Pending
- 2020-08-13 WO PCT/US2020/046069 patent/WO2021030533A1/en unknown
- 2020-08-13 EP EP20853366.1A patent/EP4013865A4/en active Pending
- 2020-08-13 AU AU2020329226A patent/AU2020329226A1/en active Pending
- 2020-08-13 US US17/634,939 patent/US20220348900A1/en active Pending
- 2020-08-13 BR BR112022002548A patent/BR112022002548A2/en unknown
- 2020-08-13 JP JP2022509126A patent/JP2022544416A/en active Pending
- 2020-08-13 CA CA3149498A patent/CA3149498A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2021030533A5 (en) | ||
US20220348900A1 (en) | Processes for purifying downstream products of in vitro transcription | |
US8084032B2 (en) | Purification method which prevents denaturation of an antibody | |
JP2010504738A5 (en) | ||
US20090005543A1 (en) | Protein-refolding material | |
TW202321446A (en) | Multicolumn chromatography mrna purification | |
GB2443505B (en) | Nucleic acid purification method | |
CN105777862A (en) | Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers | |
US20140128577A1 (en) | Purification of chimeric protein | |
US5278284A (en) | Protein purification method | |
JP2012510500A5 (en) | ||
EP2748180B1 (en) | Protein purification by anion exchange chromatography | |
JP2013194054A5 (en) | ||
RU2013112276A (en) | METHOD FOR PRODUCING IgG COMPOSITION BY HEAT PROCESSING | |
de la Llosa et al. | On the mechanism of reversible inactivation of luteinizing hormone by urea | |
CA3020959A1 (en) | Device and process for isolating nucleic acids from whole blood | |
JP2007523883A5 (en) | ||
KR100320394B1 (en) | Method for Purifying Vitamin-K-dependent Protein by Membrane Chromatography | |
RU2022106276A (en) | METHODS FOR PURIFICATION OF SUBSEQUENT TRANSCRIPTION PRODUCTS IN VITRO | |
JP4865569B2 (en) | Purification method of protein expressed in bacteria | |
US20230142167A1 (en) | A method of single strand rna purification employing an anion exchanger | |
JP3251545B2 (en) | Sperm motility promoting high molecular protein | |
CN107903301A (en) | A kind of separation method for glycosylating albumen | |
JPWO2021209595A5 (en) | ||
CN106674422A (en) | Painting mist purifying coagulant |